Patents by Inventor Kevan M. Shokat

Kevan M. Shokat has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOPHILIN BINDING AGENTS AND USES THEREOF
    Publication number: 20250108052
    Abstract: Described herein, inter alia, are immunophilin binding compounds and methods of treating CNS diseases, including co-administering outside the CNS of a subject an anti-CNS disease drug and a compound described herein.
    Type: Application
    Filed: November 22, 2024
    Publication date: April 3, 2025
    Inventors: Kevan M. Shokat, Ziyang Zhang, William A. Weiss, QiWen Fan
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20250101036
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Application
    Filed: November 22, 2024
    Publication date: March 27, 2025
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20250092061
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Application
    Filed: August 30, 2024
    Publication date: March 20, 2025
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
  • COVALENTLY BINDING INHIBITORS OF G12S, G12D AND/OR G12E MUTANTS OF K-RAS GTPASE
    Publication number: 20250059187
    Abstract: Described herein, inter alia, are GTPase inhibitors and uses thereof.
    Type: Application
    Filed: December 21, 2022
    Publication date: February 20, 2025
    Inventors: Kevan M. Shokat, Ziyang Zhang, Qinheng Zheng
  • Compositions and methods for treating cancer
    Patent number: 12116375
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Grant
    Filed: October 19, 2023
    Date of Patent: October 15, 2024
    Assignee: The Regents of the University of California
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
  • G-ALPHA-S PEPTIDE INHIBITORS AND USES THEREOF
    Publication number: 20240336657
    Abstract: Described herein, inter alia, are Gas peptide inhibitors and uses thereof.
    Type: Application
    Filed: April 26, 2022
    Publication date: October 10, 2024
    Inventors: Kevan M. Shokat, Qi Hu, Shizhong Dai, Hiroaki Suga, Rong Gao, Hayden Peacock
  • G-ALPHA-S INHIBITORS AND USES THEREOF
    Publication number: 20240336563
    Abstract: Disclosed herein, inter alia, are G-alpha-s Inhibitors and uses thereof.
    Type: Application
    Filed: April 26, 2022
    Publication date: October 10, 2024
    Inventors: Kevan M. Shokat, Qi Hu, Shizhong Dai
  • Compositions and methods for treating cancer
    Patent number: 12077507
    Abstract: Disclosed herein, inter alia, are compositions and methods for modulating Ras and treating cancer.
    Type: Grant
    Filed: March 31, 2023
    Date of Patent: September 3, 2024
    Assignee: The Regents of the University of California
    Inventors: Kevan M. Shokat, Daniel Gentile, Steven Moss
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20240109845
    Abstract: Disclosed herein, inter alia, are compositions and methods for modulating Ras and treating cancer.
    Type: Application
    Filed: March 31, 2023
    Publication date: April 4, 2024
    Inventors: Kevan M. Shokat, Daniel Gentile, Steven Moss
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20240067656
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Application
    Filed: October 19, 2023
    Publication date: February 29, 2024
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
  • Compositions and methods for treating cancer
    Patent number: 11891402
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Grant
    Filed: November 23, 2022
    Date of Patent: February 6, 2024
    Assignee: The Regents of the University of California
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
  • Compositions and methods for treating cancer
    Patent number: 11718630
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Grant
    Filed: October 27, 2022
    Date of Patent: August 8, 2023
    Assignee: The Regents of the University of California
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
  • RAS INHIBITORS AND USES THEREOF
    Publication number: 20230242586
    Abstract: Described herein, inter alia, are Ras inhibitors and uses thereof.
    Type: Application
    Filed: April 23, 2021
    Publication date: August 3, 2023
    Inventors: Kevan M. Shokat, Hiroaki Suga, Ziyang Zhang, Rong Gao
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20230242548
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Application
    Filed: November 23, 2022
    Publication date: August 3, 2023
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20230135350
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Application
    Filed: October 27, 2022
    Publication date: May 4, 2023
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
  • STABILIZATION OF MHC COMPLEXES
    Publication number: 20230111132
    Abstract: Provided, inter alia, are methods and compositions for treating cancer.
    Type: Application
    Filed: December 21, 2020
    Publication date: April 13, 2023
    Inventors: Kevan M. Shokat, Ziyang Zhang
  • KINASE ANTAGONISTS
    Publication number: 20230111917
    Abstract: The present invention provides novel compounds that are antagonists of PI3 kinase, PI3 kinase and tyrosine kinase, PI3 kinase and mTOR, or PI33 kinase, mTOR and tyrosine kinase.
    Type: Application
    Filed: March 31, 2022
    Publication date: April 13, 2023
    Inventors: Zachary A. Knight, Beth Apsel, Kevan M. Shokat
  • Compositions and methods for treating cancer
    Patent number: 11603376
    Abstract: K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: March 14, 2023
    Assignee: The Regents of the University of California
    Inventors: Jonathan Ostrem, Ulf Peters, Kevan M. Shokat
  • IMMUNOPHILIN BINDING AGENTS AND USES THEREOF
    Publication number: 20230063768
    Abstract: Described herein, inter alia, are immunophilin binding compounds and methods of heating CNS diseases, including co-administering outside the CNS of a subject an anti-CNS disease drug and a compound described herein.
    Type: Application
    Filed: February 6, 2020
    Publication date: March 2, 2023
    Inventors: Kevan M. Shokat, Ziyang Zhang, William A. Weiss, QiWen Fan
  • CHEMICALLY CONTROLLED MONOCLONAL ANTIBODY TARGET ENGAGEMENT
    Publication number: 20220289866
    Abstract: The present disclosure relates generally to antibodies reactive with tumor-specific neoantigens, as well as neoantigen-binding fragments thereof. The present disclosure also relates to nucleic acids, expression cassettes, and expression vectors encoding the antibodies and neoantigen-binding fragments. The antibodies and neoantigen binding-fragments are useful for diagnosis and treatment of cancer.
    Type: Application
    Filed: July 10, 2020
    Publication date: September 15, 2022
    Applicant: The Regents of the University of California
    Inventors: Charles S. CRAIK, Kevan M. SHOKAT, Ziyang ZHANG, Peter J. ROHWEDER